3M Health Care has received approval from the US Food and Drug Administration (FDA) for two Veraflo Therapy dressings.
The company’s Veraflo Cleanse Choice Complete dressing and V.A.C. Veraflo Cleanse Choice dressing were approved to hydromechanically remove infectious materials, non-viable tissue and wound debris.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The Veraflo Therapy dressings decrease the number of surgical debridements required and enable the formation of granulation tissue for faster wound healing.
3M Health Care clinical affairs senior vice-president and chief medical officer Dr Ronald Silverman said: “Veraflo Therapy gives wound care clinicians a proven tool to facilitate healing and reduce the need for surgical intervention.
“This FDA clearance highlights 3M innovation at its best – using science to help improve patient outcomes with better, smarter, safer health care solutions.”
Veraflo Therapy is a negative pressure wound therapy with instillation and dwell which enables the cleansing of open soft tissue wounds.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataVeraflo Therapy, in combination with either of the two approved dressings, offers a therapy that is clinically proven.
Studies also showed that the therapy can reduce the length of hospitalisation and pave the way for cost savings for the healthcare system compared to traditional wound care options.
The University of Texas Southwestern plastic surgery department and orthopaedic surgery department professor Dr Paul Kim said: “As comorbidities rise, wound healing is getting more complex.
“Solutions that help reduce the number of surgeries and accelerate healing time not only help improve patient recovery but also lower the total cost of care, creating a more efficient delivery of care for health systems.”
